IMMUNITYBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
IMMUNITYBIO, INC. (IBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 393.60 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 393.60K shares, a 51.64% decline year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 146.02K shares.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 11.22M shares, a 77.01% increase from fiscal 2024.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 6.34M shares, a 567.31% increase from fiscal 2023.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 949.58K shares, a 83.45% decline from fiscal 2022.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 5.74M shares, a 436.13% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 393.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 393.60K shares 10-Q · filed 2026-08-04 | 539.62K shares derived: sum of 3 quarters · filed 2026-08-04 | 539.62K shares derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | 146.02K shares derived: sum of 2 quarters · filed 2026-05-07 | 146.02K shares derived: sum of 3 quarters · filed 2026-05-07 | 959.95K shares derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | 146.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 146.02K shares derived: sum of 2 quarters · filed 2026-02-23 | 959.95K shares derived: sum of 3 quarters · filed 2026-02-23 | 11.22M shares 10-K · filed 2026-02-23 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 813.93K shares derived: sum of 2 quarters · filed 2025-11-05 | 11.07M shares 10-Q · filed 2025-11-05 | 11.07M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-06-30 | 813.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 11.07M shares 10-Q · filed 2025-08-05 | 11.07M shares derived: sum of 3 quarters · filed 2025-08-05 | 11.07M shares derived: sum of 4 quarters · filed 2025-08-05 | |
| 2025-03-31 | 10.26M shares 10-Q · filed 2025-05-12 | 10.26M shares derived: sum of 2 quarters · filed 2025-05-12 | 10.26M shares derived: sum of 3 quarters · filed 2025-05-12 | 10.72M shares derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-03 | 465.80K shares derived: sum of 3 quarters · filed 2025-03-03 | 6.34M shares 10-K · filed 2025-03-03 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 465.80K shares derived: sum of 2 quarters · filed 2024-11-12 | 6.34M shares 10-Q · filed 2024-11-12 | 6.34M shares derived: sum of 4 quarters · filed 2024-11-12 | |
| 2024-06-30 | 465.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 6.34M shares 10-Q · filed 2024-08-12 | 6.34M shares derived: sum of 3 quarters · filed 2024-08-12 | 6.34M shares derived: sum of 4 quarters · filed 2024-08-12 | |
| 2024-03-31 | 5.87M shares 10-Q · filed 2024-05-09 | 5.87M shares derived: sum of 2 quarters · filed 2024-05-09 | 5.87M shares derived: sum of 3 quarters · filed 2024-05-09 | 6.82M shares derived: sum of 4 quarters · filed 2024-05-09 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-19 | 949.58K shares derived: sum of 3 quarters · filed 2024-03-19 | 949.58K shares 10-K · filed 2024-03-19 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 949.58K shares derived: sum of 2 quarters · filed 2023-11-09 | 949.58K shares 10-Q · filed 2023-11-09 | 949.58K shares derived: sum of 4 quarters · filed 2023-11-09 | |
| 2023-06-30 | 949.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 949.58K shares 10-Q · filed 2023-08-08 | 949.58K shares derived: sum of 3 quarters · filed 2023-08-08 | 949.58K shares derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | 0.00 shares derived: sum of 2 quarters · filed 2023-05-11 | 0.00 shares derived: sum of 3 quarters · filed 2023-05-11 | 1.01M shares derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-01 | 1.01M shares derived: sum of 3 quarters · filed 2023-03-01 | 5.74M shares 10-K · filed 2023-03-01 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 1.01M shares derived: sum of 2 quarters · filed 2022-11-09 | 5.74M shares 10-Q · filed 2022-11-09 | 5.74M shares derived: sum of 4 quarters · filed 2022-11-09 | |
| 2022-06-30 | 1.01M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 5.74M shares 10-Q · filed 2022-08-08 | 5.74M shares derived: sum of 3 quarters · filed 2022-08-08 | ||
| 2022-03-31 | 4.73M shares 10-Q · filed 2022-05-10 | 4.73M shares derived: sum of 2 quarters · filed 2022-05-10 | |||
| 2022-03-23 | 4.73M shares 10-K · filed 2023-03-01 | ||||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 1.07M shares 10-K · filed 2022-03-01 | |||
| 2021-09-30 | 1.07M shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |